Executive Summary of the Vulvodynia Therapeutic Research Summit.
Study Design
- Loại nghiên cứu
- Other
- Đối tượng nghiên cứu
- expert consensus on therapeutics for provoked vestibulodynia
- Can thiệp
- Executive Summary of the Vulvodynia Therapeutic Research Summit. None
- Đối chứng
- None
- Kết quả chính
- None
- Xu hướng hiệu quả
- Neutral
- Nguy cơ sai lệch
- Unclear
Abstract
The current treatment of provoked vestibulodynia involving neuroproliferation is often complete vestibulectomy; however, less invasive treatments are biologically plausible, yet lack study. The International Society for the Study of Women's Sexual Health, the National Vulvodynia Association, the Gynecologic Cancers Research Foundation, and Tight Lipped, a grassroots nonprofit organization that supports people with chronic vulvovaginal and pelvic pain, collectively sponsored a conference, the Vulvodynia Therapeutic Research Summit, held in April 2024. The primary objective of the Vulvodynia Therapeutic Research Summit was to identify options for further research of the treatment of provoked vestibulodynia through expert consensus. After the conference, attendees scored the presented therapeutics in rank order, leading to a hierarchy of merit. Fifteen therapeutic options were presented and ranked in order of most promising to least promising for further study on treating the neuroinflammation of provoked vestibulodynia. The top identified therapeutics for further research were: 1) ketotifen fumarate (mast cell stabilizer with potential to prevent mast cell activation), 2) resiniferatoxin (transient receptor vanilloid 1 agonist causing chemo-inactivation of nerve terminals), 3) specialized pro-resolving mediators or strategies to boost their levels (eg, maresin 1 and 1-trifluoromethoxy-phenyl-3-[1-propionylpiperidin-4-yl] urea), 4) luteolin (flavonoid with potent anti-inflammatory, antioxidant, and neuroprotective properties), 5) alpha-lipoic acid (antioxidant with nerve-specific anti-inflammatory and mast cell stabilizing qualities), and 6) NGFR121W -SNAP IR700 trimer exposed to near-infared light (photoablation targeting nociceptors and sparing surrounding tissue). This executive summary describes the rationale for identifying specific pharmacologic agents and medical devices as targets for research directed toward treatment of the neuroinflammatory process found in the vestibular mucosa of provoked vestibulodynia.
Tóm lược
The rationale for identifying specific pharmacologic agents and medical devices as targets for research directed toward treatment of the neuroinflammatory process found in the vestibular mucosa of provoked vestibulodynia is described.
Used In Evidence Reviews
Similar Papers
International journal of sport nutrition and exercise metabolism · 2018
Dietary Supplements for Health, Adaptation, and Recovery in Athletes.
Brain research. Molecular brain research · 2005
Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro.
Neurochemistry international · 2016
Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease.
Brain, behavior, and immunity · 2020
Macrophages and Schwann cell TRPA1 mediate chronic allodynia in a mouse model of complex regional pain syndrome type I.
Neurochemistry international · 2017
Alpha-lipoic acid attenuates acute neuroinflammation and long-term cognitive impairment after polymicrobial sepsis.
Clinical nutrition (Edinburgh, Scotland) · 2009